📇 Rhumatologue · HEROUVILLE ST CLAIR · (14) · Libéral

MME NINA QUEDRU-SERRA

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 HEROUVILLE ST CLAIR (14)LibéralRPPS 10002113388

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CABINET DU DR NINA QUEDRU-SERRA
POLE DE SANTE DU GRAND PARC 2 PLACE PIERRE ET MARIE CURIE, 14200 HEROUVILLE ST CLAIR
☎ 0231955857Activité de soin et de pharmacie

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis

International journal of women's dermatology · 2022

📚 52 citations🎯 RCR 6.81Top 5% NIH🔓 Open Access

Lire l'abstract Crossref ↓

Background: Psoriasis is a common chronic inflammatory skin disease with an exceptionally high burden for women. Objective: Sex-dependent differences in disease manifestation, severity, treatment choices, subjective disease perception, and the impact on quality of life and risk factors are described and comprehensively discussed. Methods: A literature search was conducted using MEDLINE (PubMed) and the Cochrane Library for systematic reviews to investigate the challenges in treating women with psoriasis. Results and conclusions: The incidence, prevalence, and manifestation of psoriasis of the skin are similar between different sexes. Genetic and environmental factors such as obesity and metabolic syndrome are risk factors and are not equally relevant or pronounced in women and men. Overall, women have a lower disease severity measured by the Psoriasis Area Severity Index, which is associated with a higher impairment of their life quality measured by the Dermatology Life Quality Index compared with men. In addition, women with psoriasis are more likely to have depression than men. Hormonal factors affect psoriasis, with a correlation of high estrogen levels and improvement of psoriasis. Data regarding differences in prescribing patterns of systemic treatments and the severity of psoriasis are not entirely consistent. Registry studies show that men tend to have more severe psoriasis and, in some cases, are prescribed systemic therapies more frequently. Women tend to respond better to systemic treatments and to experience more adverse events. Treatment options are the same for both sexes, except during pregnancy and lactation. Various treatment options are contraindicated due to fear of fetal or neonate harm and lack of data. Topical steroids can be prescribed with a high degree of safety during pregnancy. For other topical therapies (calcineurin inhibitors and vitamin D analogs), no studies of adverse effects in pregnancy are available, and safety data mainly stem from studies examining effects after systemic administration. Antitumor necrosis factor monoclonal antibodies (except for certolizumab pegol) have been associated with a possible increased risk of preterm birth, low gestational age, and cesarean deliveries. Prospective data on the safety of biologics other than antitumor necrosis factor-alpha antibodies to accurately assess whether novel biologics (eg, anti-interleukin 17, 12/23, 23) can be used for systemic therapy in pregnancy are lacking or currently being conducted.

Basin-wide variation in tree hydraulic safety margins predicts the carbon balance of Amazon forests

Nature · 2023

📚 40 citations🎯 RCR 6.06Top 6% NIH🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

AbstractTropical forests face increasing climate risk1,2, yet our ability to predict their response to climate change is limited by poor understanding of their resistance to water stress. Although xylem embolism resistance thresholds (for example, $$\varPsi $$ Ψ 50) and hydraulic safety margins (for example, HSM50) are important predictors of drought-induced mortality risk3–5, little is known about how these vary across Earth’s largest tropical forest. Here, we present a pan-Amazon, fully standardized hydraulic traits dataset and use it to assess regional variation in drought sensitivity and hydraulic trait ability to predict species distributions and long-term forest biomass accumulation. Parameters $$\varPsi $$ Ψ 50 and HSM50 vary markedly across the Amazon and are related to average long-term rainfall characteristics. Both $$\varPsi $$ Ψ 50 and HSM50 influence the biogeographical distribution of Amazon tree species. However, HSM50 was the only significant predictor of observed decadal-scale changes in forest biomass. Old-growth forests with wide HSM50 are gaining more biomass than are low HSM50 forests. We propose that this may be associated with a growth–mortality trade-off whereby trees in forests consisting of fast-growing species take greater hydraulic risks and face greater mortality risk. Moreover, in regions of more pronounced climatic change, we find evidence that forests are losing biomass, suggesting that species in these regions may be operating beyond their hydraulic limits. Continued climate change is likely to further reduce HSM50 in the Amazon6,7, with strong implications for the Amazon carbon sink.

Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

Arthritis & rheumatology (Hoboken, N.J.) · 2025

📚 14 citations🎯 RCR 5.96🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

ObjectiveOur objective was to assess the incidence of major adverse cardiovascular events (MACEs) in patients with rheumatoid arthritis (RA) treated with JAK inhibitors (JAKi), tumor necrosis factor inhibitors (TNFi), or biologic disease‐modifying antirheumatic drugs with other modes of action (bDMARD‐OMA) in a multicountry, real‐world population.MethodsPatients with RA from 15 registries in the JAK‐pot collaboration were included. MACE incidence was analyzed using two approaches: a within‐registry analysis aggregating country‐specific estimates from registers with >25 incident MACEs through meta‐analysis and an individual‐level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRRs) of MACEs between treatment groups, accounting for multiple treatment courses.ResultsThe study included 73,008 treatment courses (16,417 JAKi, 35,373 TNFi, and 21,218 bDMARD‐OMA) and 828 incident MACEs among 51,233 patients. Median follow‐up time was 1.3 years, with most of the follow‐up concentrated in the first two years of treatment. Incidence rates were 7.0, 7.6, and 11.8 per 1,000 person‐years for JAKi, TNFi, and bDMARD‐OMA, respectively. Compared to TNFi, JAKi (within‐registry adjusted IRR 0.89, 95% confidence interval [CI] 0.63–1.25) had similar incidence rates of MACEs and bDMARD‐OMA had higher rates (within‐registry adjusted IRR 1.35, 95% CI 1.10–1.66). Combined analysis showed similar results.ConclusionObservational data from the JAK‐pot collaboration show no evidence of an increase in cardiovascular events during the first two years of use with JAKi compared to TNFi in the general RA population.

Cookies & analyse de trafic

MME NINA QUEDRU-SERRA

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal33

Épidémiologie & registres5

Case report / série2

Pédiatrie2

Pharmacovigilance2

Qualité de vie / PROMs2

Lupus1

Microbiote1

Ostéoporose1

Revue générale1

Santé mentale / fatigue1

Vascularites des gros vaisseaux1

Vraie vie / RWE1

Partager cette fiche